Winship Cancer Institute of Emory University | Strategic Alliance Partners

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

Sacituzumab govitecan displayed efficacy in terms of PFS both with/without pembrolizumab in patients with untreated TNBC.

Safety analysis shows sacituzumab govitecan plus pembrolizumab has a manageable profile and fewer dose reductions than chemoimmunotherapy in PD-L1+ TNBC.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Dr Kalinsky discusses the treatment paradigm for HR-positive breast cancer post-CDK4/6 inhibition and the need for therapeutic advances in this setting.

Kevin Kalinsky, MD, MS, FASCO, discusses research needs to improve treatment strategies in the post-CDK4/6 inhibitor setting for HR-positive breast cancer.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

Winship Cancer Institute of Emory University has launched a mobile prostate cancer screening program.

Luis E. Raez, MD, and Suresh S. Ramalingam, MD, FACP, FASCO, sit down with Chandler Park, MD, FACP, and Eric K. Singhi, MD, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Leal and Nagasaka discussed the significance of the FDA approval of zongertinib for previously treated patients with HER2 TKD–mutant advanced NSCLC.

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Kevin Kalinsky, MD, MS, FASCO, discusses how findings from SERENA-6 reinforce the importance of timely ESR1 testing in HR-positive breast cancer.

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

Ribociclib plus a nonsteroidal aromatase inhibitor improved iDFS, DDFS, RFS, and DRFS in HR+/HER2– early breast cancer.

Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

Kevin Kalinsky, MD, MS, discusses the potential to switch CDK4/6 inhibitors in HR-positive metastatic breast cancer.

Neoadjuvant lenvatinib plus pembrolizumab followed by adjuvant pembrolizumab was safe and effective in patients with locally advanced, nonmetastatic ccRCC.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.

Anthony M. Hunter, MD, discusses the development of, and future roles for JAK, BET, and BCL2/BCL-XL inhibitors in myelofibrosis.

Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.

Kevin Kalinsky, MD, MS, discusses outcomes of the phase 3 postMONARCH study in hormone receptor–positive, HER2-negative advanced breast cancer.

Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.

Jacqueline Brown, MD, discusses the nuanced potential role of immunotherapy-ADC and dual-ADC combinations in bladder cancer.

Jacqueline Brown, MD, explains the need to determine optimal second-line bladder cancer treatments for use after enfortumab vedotin/pembrolizumab.

Jacqueline Brown, MD, discusses the current role of enfortumab vedotin plus pembrolizumab in bladder cancer and tips for early AE management.